Jin Y, Lorvik K, Jin Y, Beck C, Sike A, Persiconi I, et al. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. Mol Ther Oncolytics. 2022;26:189-206 pubmed publisher

Meggyes M, Feik T, Nagy D, Polgar B, Szereday L. CD8 and CD4 Positive NKT Subpopulations and Immune-Checkpoint Pathways in Early-Onset Preeclampsia and Healthy Pregnancy. Int J Mol Sci. 2023;24: pubmed publisher

Lao L, Zeng W, Huang P, Chen H, Jia Z, Wang P, et al. CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance. Cancer Immunol Res. 2023;11:320-338 pubmed publisher

Edwards C, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, et al. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br J Cancer. 2021;: pubmed publisher

Geuijen C, Tacken P, Wang L, Klooster R, Van Loo P, Zhou J, et al. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12:4445 pubmed publisher

Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, et al. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29:1794-1807 pubmed publisher

Cunningham R, Holland M, McWilliams E, Hodi F, Severgnini M. Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. J Biol Methods. 2019;6:e114 pubmed publisher

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019;7:209 pubmed publisher